Laxido Orange

Macrogol 3350, the active ingredient in Laxido Orange, is an osmotic laxative presented as a powder for oral solution for oral use. It is indicated for the relief of occasional constipation in adults and children when dietary measures are insufficient.

GNH USA supplies Laxido Orange as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant packaging for global distribution, offering reliable lead times and comprehensive technical support throughout the supply chain.

Laxido Orange (macrogol 3350) is an osmotic laxative used to manage constipation.

- Occasional constipation: softens stool and facilitates regular bowel movements. - Functional constipation: improves stool frequency and consistency in chronic cases. - Opioid‑induced constipation: alleviates reduced bowel motility associated with opioid therapy.

Macrogol 3350 may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal bloating - Flatulence - Nausea - Diarrhea - Abdominal cramps - Headache

Serious or Rare Side Effects: - Severe dehydration - Electrolyte imbalance (e.g., hyponatremia, hypokalemia) - Allergic reactions such as rash or angioedema - Severe abdominal pain - Rectal bleeding - Anaphylaxis (rare)

Before using Laxido Orange, consider the following precautions to ensure safe and effective therapy.

- Assess renal function: avoid or adjust use in patients with severe renal impairment. - Monitor electrolytes: the formulation contains sodium, potassium and chloride, requiring periodic electrolyte assessment. - Avoid in intestinal obstruction: contraindicated in mechanical blockage of the bowel. - Use with caution in the elderly: increased susceptibility to dehydration and electrolyte shifts. - Pregnancy and lactation: consult a healthcare professional before use, as safety data are limited. - Store at ambient temperature: keep the powder in its original container, protect from moisture and heat.

Macrogol 3350 can interact with other medicines, affecting electrolyte balance or renal function.

Major Interactions (Avoid): - Concurrent use with other osmotic laxatives: risk of severe electrolyte disturbance. - Combination with loop diuretics: may exacerbate loss of sodium and potassium. - Co‑administration with high‑dose NSAIDs: increased potential for renal impairment.

Moderate Interactions (Monitor Closely): - Use with antacids containing sodium or potassium: additive electrolyte load may require monitoring. - Concomitant digoxin therapy: monitor serum potassium levels to avoid toxicity. - Concurrent corticosteroid therapy: observe fluid and electrolyte status closely.